ERX research wins AACR award

San Diego, CA - April 20, 2026. Durga Paneerdoss, an undergraduate working in the laboratory of EtiraRx founder Ratna Vadlamudi received the Third Place Prize in the Margaret Foti Foundation Undergraduate Student Prize competition at the AACR…

Etira chosen for Mass Challenge!

Dallas, TX - April 14, 2026 We are pleased to announce that EtiraRx has been selected for the 2025 MassChallenge U.S. Early Stage Healthcare Cohort — a highly selective, zero-equity accelerator! This puts us alongside a global network of…

ERX-41 shows activity in rare aggressive Breast Cancer subtype

San Antonio, TX - March 23, 2026.We are pleased to present our new open-access paper in Biomolecules (link here).Our paper shows activity of ERX-41 in Inflammatory breast cancer (IBC), a rare (2–4%) extremely aggressive subset of breast…

Optimization of LIPA targeting in Ovarian Cancer

San Antonio TX, February 06, 2026Introducing ERX-208 - our supercharged ERX-41 analog for ovarian cancer!Publication in Oncogene shows the same powerful MOA of inducing uncompensated ER stress, but ERX-208 delivers dramatically higher…

Etira Board Member recognized in 2026 King’s New Year Honors

Congratulations to Dr Annalisa Jenkins OBE, a member of Etira’s Board of Directors, who has been appointed an Officer of the Order of the British Empire (OBE) in The King’s New Year Honours for her contributions to the life sciences.

Etira Founder’s Scientific Journey Highlighted

San Antonio, TX – November 18, 2025. Etira Founder Professor Ratna Vadlamudi delivered a compelling, deeply personal narrative as the featured speaker at the Health Cell State of the Industry event at the Tobin Center in San Antonio.

Etira CEO Featured In Clinical Leader for R&D Efficiency

Philadelphia, PA – July 16, 2025: In an article just published in Clinical Leader magazine entitled "How An Australia-First Strategy Cut 63% From Our R&D Spend", Etira CEO Russell Hayward explains how our strategic decision to conduct…

Progress in ERX-315 Phase 1 Clinical Trial

Dallas, Texas — June 26, 2025: Etira, a clinical-stage biopharmaceutical company aiming to develop cancer therapies, announced today that the first patient has been successfully treated at Dose Level Four (DL4) in its ongoing Phase 1 clinical…

Etira Expands Clinical Trial Sites

Sydney, Australia – June 2, 2025: Etira, a clinical-stage biopharmaceutical company focused on developing cancer therapies, announced the activation of a new trial site at Macquarie University Hospital (MUH) in Sydney, New South Wales. The…

Research on Etira drugs win awards at AACR 2025

Chicago, IL – April 30, 2025:Presenters of two abstracts with preclinical data on ERX-208 and ERX-315 have won awards at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.Adriana Baker, who presented…